The new angiotensin II receptor antagonist, irbesartan: Pharmacokinetic and pharmacodynamic considerations

American Journal of Hypertension

Volumn 10, Issue 12 II SUPPL., 1997, Pages

  Brunner, Hans R ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Angiotensin II receptor antagonist; Irbesartan; Losartan; Pharmacodynamics; Pharmacokinetics

Indexed keywords

ANGIOTENSIN 2 RECEPTOR ANTAGONIST; CANDESARTAN; IRBESARTAN; LOSARTAN; TASOSARTAN;

BIOAVAILABILITY; BIOTRANSFORMATION; BLOOD PRESSURE REGULATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG TOLERABILITY; HUMAN; HYPERTENSION; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 0031418316     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(97)00391-9     Document Type: Article

References (27)

1. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev. 45:1993;205-251.
2. Vachharajani N, Chang S-Y, Shyu WC, et al. Absolute bioavailability of irbesartan, an angiotensin II receptor antagonist, in man (abst). Pharm Res. 12:1995;S418.
3. COZAAR. Losartan potassium tablets. Prescribing information, package insert, Merck & Co., West Point, PA, 1997.
4. Diovan. Valsartan capsules. Prescribing information, package insert, Novartis, East Hanover, NJ, 1997.
5. Marino MR, Langenbacher KM, Ford NF, Uderman HD. Safety, tolerability, pharmacokinetics and pharmacodynamics of irbesartan after single and multiple doses in healthy male subjects (abst). Clin Pharmacol Ther. 61:1997;207.
6. Necciari J, Denolle T, Le Coz F. Pharmacokinetics of SR 47436 (BMS 186295), a new angiotensin II receptor antagonist in man (abst). J Hypertens. 12:1994;88.
7. Vachharajani N, Shyu WC, Mantha S, et al. Lack of food effect on the oral bioavailability of irbesartan (abst). J Clin Pharmacol. 37:1997;872.
8. Morimoto S, Ogihara T. TCV-116 a new angiotensin II type-1 receptor antagonist . Cardiovasc Drug Rev. 12:1994;153-164.
9. 1 subtype angiotensin II receptor antagonist. J Pharmacol Exp Ther. 265:1993;826-834.
10. Wong PC, Price WA Jr, Chiu AT, et al. Nonpeptide angiotensin II receptor antagonists XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent . J Pharmacol Exp Ther. 255:1990;211-217.
11. Neefe DL, Klamerus KJ, Battle MM, Mayer PR. Multiple dose safety, pharmacokinetic (PK) and pharmacodynamic study of tasosartan in patients with mild to moderate hypertension (abst). Am J Hypertens. 104, part 2):1997;105A.
12. Perrier L, Bourrié M, Marti E, et al. In vitro N-glucuronidation of SR 47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human hepatic microsomal fractions. J Pharmacol Exp Ther. 271:1994;91-99.
13. Sica DA, Marino MR, Gehr TWB, et al. Pharmacokinetics of irbesartan not altered by renal impairment or hemodialysis (abst). Nephrology. 3:(suppl 1):1997;S519.
14. Marino MR, Langenbacher KM, Raymond RH, et al. Pharmacokinetics and pharmacodynamics of irbesartan in subjects with hepatic cirrhosis (abst). J Clin Pharmacol. 37:1997;871.
15. Vachharajani N, Shyu WC, Smith R, et al. The effects of age and gender on the pharmacokinetics of irbesartan (abst). Pharm Res. 12:1995;S388.
16. Vachharajani N, Shyu WC, Greene D, Barbhaiya R. The effect of age on the pharmacokinetics of irbesartan (abst). J Clin Pharmacol. 37:1997;872.
17. Marino MR, Hammett JL, Ferreira I, et al. Lack of effect of nifedipine on the pharmacokinetics of irbesartan in healthy male subjects (abst). J Clin Pharmacol. 37:1997;872.
18. Marino MR, Langenbacher KM, Ford NF, et al. Effect of hydrochlorothiazide on the pharmacokinetics and pharmacodynamics of irbesartan (abst). Clin Pharmacol Ther. 61:1997;207.
19. Christophe B, Libon R, Cazaubon C, et al. Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat potential mechanisms of action . Eur J Pharmacol. 281:1995;161-171.
20. Ribstein J, Sissmann J, Picard A, et al. Effects of the angiotensin II antagonist SR 47436 (BMS 186295) on the pressor response to exogenous angiotensin II and the renin-angiotensin system in sodium replete normal subjects (abst). J Hypertens. 12:1994;131.
21. Ribstein J, Picard A, Armagnac C, et al. Full antagonism of pressor response to exogenous angiotensin II (AII) by single-dose irbesartan in normotensive subjects (abst). J Hypertens. 15:(suppl 4):1997;S117.
22. Christen Y, Waeber B, Nussberger J. Dose-response relationships following oral administration of DuP 753 to normal humans. Am J Hypertens. 4:1991;350S-353S.
23. Christen Y, Waeber B, Nussberger J, et al. Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal volunteers inhibition of pressor response to exogenous angiotensin I and II . Circulation. 83:1991;1333-1342.
24. Munafo A, Christen Y, Nussberger J, et al. Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist. Clin Pharmacol Ther. 51:1992;513-521.
25. Pouleur HG. Clinical overview of irbesartan a new angiotensin II receptor antagonist . Am J Hypertens. 10:1997;318S-324S.
26. Nelson E, Arcuri K, Ikeda L, et al. Efficacy and safety of losartan in patients with essential hypertension (abst). Am J Hypertens. 5:1992;19A.
27. Weber MA. Clinical experience with the angiotensin II receptor antagonist losartan A preliminary report . Am J Hypertens. 5:1992;247S-251S.